Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | RARG | P13631 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330571 | 0.84 | RARB (0.50) | RARARARBRARGERN1KCNJ1 | |
| SCHEMBL5331991 | 0.65 | RARB (0.50) | RARARARBRARGMEN1KMT2A | |
| SCHEMBL21793428 | 0.63 | EGFR (0.43) | ERN1ALDH1A1 | |
| SCHEMBL5329024 | 0.63 | RARB (0.55) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7773469 | 0.62 | RARB (0.63) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8771704 | 0.61 | RARA (0.70) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL10200927 | 0.61 | CYP2A6 (0.46) | ERN1ALDH1A1 | |
| SCHEMBL2972320 | 0.58 | NPC1 (0.37) | RARARARBRARGMEN1ALDH1A1 | |
| SCHEMBL16511765 | 0.58 | ALDH1A1 (0.41) | ERN1MEN1ALDH1A1MPIKMT2A | |
| SCHEMBL25366979 | 0.57 | ESR2 (0.42) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, NR2E3, RARG | RARA 8/4885RARB 7/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.